Social Determinants of Health Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-analysis

Further Publications

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Clin Gastroenterol Hepatol

Faulkner CS, Aboona MB, Surendra L, Rangan P, Ng CH, Huang DQ, Muthiah M, Kim D, Fallon MB, Noureddin M, Chen VL, Kardashian A, Wijarnpreecha K

doi: 10.1016/j.cgh.2024.10.019

Hepatology

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Hepatology

Unalp-Arida A, Ruhl CE

doi: 10.1097/HEP.0000000000001211

Hepatology

Association of Food Insecurity with the Prevalence and Liver-related Mortality of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

J Hepatol

Younossi ZM, Zelber-Sagi S, Kuglemas C, Lazarus JV, Paik A, de Avila L, Gerber L, Paik JM

doi: 10.1016/j.jhep.2024.08.011

Hepatology

High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: a Meta-Analysis

Clin Gastroenterol Hepatol

Kit Ho GJ, Ning Tan FX, Sasikumar NA, Jun Tham EK, Ko D, Kim DH, Danpanichkul P, Yu Z, Xianda C, Zhang ZX, Wijarnpreecha K, Pramotedham T, Noureddin M, Huang DQ, Sumida Y, Nakajima A, Zheng MH, Takahashi H, Ng CH, Muthiah M

doi: 10.1016/j.cgh.2025.02.006

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Hepatology

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Lancet Gastroenterol Hepatol

Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL

doi: 10.1016/S2468-1253(24)00320-0

Hepatology

Prevalence of subclinical hypothyroidism and longitudinal thyroid stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: an observational study

Hepatology

Untalan M, Crimmins N, Yates KP, Mencin A, Xanthakos S, Thaker VV

doi: 10.1097/HEP.0000000000001095

Hepatitis

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis

Hepatology

Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R

doi: 10.1097/HEP.0000000000001254

Related content

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Association of Food Insecurity with the Prevalence and Liver-related Mortality of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: a Meta-Analysis

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Prevalence of subclinical hypothyroidism and longitudinal thyroid stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: an observational study

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis